Korean Circulation Journal

  • 제52권5호
  • /
  • Pages.354-364
  • /
  • 2022
  • /
  • 1738-5520(pISSN)
  • /
  • 1738-5555(eISSN)
대한심장학회 (The Korean Society of Cardiology)
권호 표지
DOI QR코드

DOI QR Code

Osstem Cardiotec Centum Stent Versus Xience Alpine Stent for De Novo Coronary Artery Lesion: A Multicenter, Randomized, Parallel-Designed, Single Blind Test

  • Chang-Hwan Yoon (Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital) ;
  • Jihong Jang (Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital) ;
  • Seung Ho Hur (Division of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Medical Center) ;
  • Jun-Hee Lee (Division of Cardiology, Department of Internal Medicine, Kangdong Sacred Heart Hospital) ;
  • Seung Hwan Han (Division of Cardiology, Department of Internal Medicine, Gachon University Gil Medical Center) ;
  • Soon-Jun Hong (Division of Cardiology, Department of Internal Medicine, Korea University Anam Hospital) ;
  • Kiyuk Chang (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea Seoul St. Mary's Hospital) ;
  • In-Ho Chae (Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital)
  • 투고 : 2021.06.03
  • 심사 : 2021.12.07
  • 발행 : 2022.05.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background and objectives: To compare the safety and efficacy of a new everolimus-eluting stent with an abluminal-coated biodegradable polymer (Osstem Cardiotec Centum) with those of the Xience Alpine stent (Xience). Methods: This randomized, prospective, multicenter, parallel-designed, single-blind trial was conducted among patients with myocardial ischemia undergoing percutaneous coronary intervention (PCI) from 21st September 2018 until 3rd July 2020. The primary efficacy endpoint was in-segment late lumen loss (LLL) at 270 days after the procedure and the primary safety endpoints were major adverse cardiac events (MACE), composite of cardiac death, myocardial infarction, and target lesion revascularization. Results: We enrolled 121 patients and analyzed 113 patients who finished 270 days of follow-up for the primary efficacy endpoint. The mean age of the participants was 66.8 years. As for the primary efficacy endpoint, LLL of the Osstem Cardiotec Centum group was 0.09±0.13 mm and that of the Xience group was 0.12±0.14 mm (upper limit of 1-sided 95% confidence interval, 0.02; p for non-inferiority, 0.0084). This result demonstrates the non-inferiority of the Osstem Cardiotec Centum. As for the primary safety endpoint, MACE occurred in one patient (1.59% of the Xience group). Meanwhile, no MACE occurred in the Osstem Cardiotec Centum group. Conclusions: The Osstem Cardiotec Centum is non-inferior to the Xience Alpine® stent and is confirmed to be safe. It could be safely and effectively applied to patients with coronary artery disease undergoing PCI.

키워드

과제정보

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI18C2332).

참고문헌

  1. Stefanini GG, Holmes DR Jr. Drug-eluting coronary-artery stents. N Engl J Med 2013;368:254-65. https://doi.org/10.1056/NEJMra1210816
  2. Kang SH, Gogas BD, Jeon KH, et al. Long-term safety of bioresorbable scaffolds: insights from a network meta-analysis including 91 trials. EuroIntervention 2018;13:1904-13. https://doi.org/10.4244/EIJ-D-17-00646
  3. Zanchin C, Ueki Y, Zanchin T, et al. Everolimus-eluting biodegradable polymer versus everolimus-eluting durable polymer stent for coronary revascularization in routine clinical practice. JACC Cardiovasc Interv 2019;12:1665-75. https://doi.org/10.1016/j.jcin.2019.04.046
  4. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010;363:136-46. https://doi.org/10.1056/NEJMoa1004130
  5. Stone GW, Sabik JF, Serruys PW, et al. Everolimus-eluting stents or bypass surgery for left main coronary artery disease. N Engl J Med 2016;375:2223-35. https://doi.org/10.1056/NEJMoa1610227
  6. Raber L, Magro M, Stefanini GG, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 2012;125:1110-21. https://doi.org/10.1161/CIRCULATIONAHA.111.058560
  7. Stone GW, Midei M, Newman W, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008;299:1903-13. https://doi.org/10.1001/jama.299.16.1903
  8. Meredith IT, Whitbourn R, Scott D, et al. PLATINUM QCA: a prospective, multicentre study assessing clinical, angiographic, and intravascular ultrasound outcomes with the novel platinum chromium thin-strut PROMUS Element everolimus-eluting stent in de novo coronary stenoses. EuroIntervention 2011;7:84-90. https://doi.org/10.4244/EIJV7I1A15
  9. Gao RL, Xu B, Lansky AJ, et al. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial. EuroIntervention 2013;9:75-83. https://doi.org/10.4244/EIJV9I1A12
  10. Windecker S, Haude M, Neumann FJ, et al. Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial. Circ Cardiovasc Interv 2015;8:e001441.
  11. Guagliumi G, Sirbu V, Musumeci G, et al. Examination of the in vivo mechanisms of late drug-eluting stent thrombosis: findings from optical coherence tomography and intravascular ultrasound imaging. JACC Cardiovasc Interv 2012;5:12-20. https://doi.org/10.1016/j.jcin.2011.09.018
  12. Mori M, Sakata K, Nakanishi C, et al. Early endothelialization associated with a biolimus A9 bioresorbable polymer stent in a porcine coronary model. Heart Vessels 2017;32:1244-52. https://doi.org/10.1007/s00380-017-0992-5
  13. Puranik AS, Dawson ER, Peppas NA. Recent advances in drug eluting stents. Int J Pharm 2013;441:665-79. https://doi.org/10.1016/j.ijpharm.2012.10.029
  14. von Birgelen C, Kok MM, van der Heijden LC, et al. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial. Lancet 2016;388:2607-17. https://doi.org/10.1016/S0140-6736(16)31920-1
  15. Kandzari DE, Mauri L, Koolen JJ, et al. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. Lancet 2017;390:1843-52. https://doi.org/10.1016/S0140-6736(17)32249-3